Equity Overview
Price & Market Data
Price: $1.59
Daily Change: $0.00 / 0.00%
Daily Range: $1.40 - $1.72
Market Cap: $22,807,016
Daily Volume: 204,170
Performance Metrics
1 Week: -4.22%
1 Month: -32.05%
3 Months: -44.60%
6 Months: -84.33%
1 Year: -83.90%
YTD: -44.60%
Company Details
Employees: 25
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.